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Abstract
Background: The POU-domain transcription factor Oct-6 has been reported to be differentially
expressed between schizophrenic and control post-mortem brains. In this study, we attempted to
replicate this finding and to discover whether Oct-6 was also dysregulated in bipolar disorder and
major depression.
Methods: Oct-6 mRNA and protein expression were determined by in-situ hybridization and
immunohistochemistry respectively in sections of post-mortem brain.
Results: We did not observe any differences in Oct-6 expression between any of the groups under
study. Oct-6 mRNA and protein was identically expressed in the hippocampal and cortical regions
of most specimens in all groups, including controls.
Conclusion: Oct-6 is, therefore, unlikely to be a specific marker for any psychological disorder;
rather its expression in controls suggests that it is normally expressed in most adult brains.
Background
The neurodevelopmental hypothesis of schizophrenia
proposes that events occurring during foetal develop-
ment, which adversely effect the development of the
brain, may underlie the occurrence of schizophrenia in
later life [1]. One approach to try to investigate this
hypothesis has been to examine genes involved in the nor-
mal development of the brain and determine whether
they are altered in schizophrenia.
The POU-domain homeobox transcription factors are one
such family of genes involved in development. We have
focused on Oct-6 (SCIP/Tst-1/POU3f1), a member of the
POU-III subfamily. Much of the initial work on Oct-6
looked at its role in the peripheral nervous system, in par-
ticular its role in Schwann cell development, where it is
required for the timely initiation of myelination [2]. Oct-
6 has also been shown to be expressed in postmitotic neu-
rons of the developing rodent telencephalon as they
migrate from the ventricular to the intermediate zone, and
is particularly associated with those destined for cortical
layers II/III and V. Oct-6 is expressed in these cortical lam-
inae and in the CA1 region of the adult hippocampus
[3,4], although some rodent data has suggested that all
Oct-6 expression is eventually lost with age [5].
A previous open study has reported the expression of
OCT-6 protein in the frontal and temporal lobes of
patients diagnosed with schizophrenia but its absence
from matched controls, suggesting it may be a putative
biological marker for schizophrenia [6]. Affective disor-
ders such as bipolar disorder and major depression share
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many of the symptoms seen in schizophrenia (DSM-IV)
[7], and it has been suggested that a common pathology
may underlie schizophrenia and bipolar disorder [8-10].
The potential importance of POU factors in affective dis-
orders was highlighted by a study by Stopkova et al
(2004) who reported that a polymorphism within the
PIK3C3 promoter, linked to a subset of schizophrenic and
bipolar patients. Stopkova et al (2004) suggest that the -
432C→T polymorphism, occurring as it does within an
octamer binding site (the DNA motif recognised by POU
domain transcription factors), may affect POU protein
binding to this region [11]. Expression assays in neural
stem cell lines have shown that Oct-6-induced expression
of the reporter is indeed decreased by the presence of this
polymorphism (personal communication, Dafe
Uwanogho).
We aimed to replicate the initial finding of Oct-6 expres-
sion in the brains of patients diagnosed with schizophre-
nia and to extend this finding to bipolar disorder and
major depression in order to determine whether Oct-6
expression was specific to schizophrenia or a more general
marker of psychosis.
Methods
Tissue acquisition
A total of 60 subjects from the Stanley Foundation Neu-
ropathology Consortium were used in these studies. This
set consists of 15 samples from patients with schizophre-
nia, 15 with major depressive disorder, 15 with bipolar
disorder, and 15 matched controls patients. A detailed
description of this collection has been published [12],
and a summary of subject characteristics is shown in Table
1.
Cryostat and paraffin sectioned slides were provided by
the Stanley Foundation. They were stored at -80°C and
room temperature, respectively, until use. The sections
were coded, the investigator had no knowledge of the dis-
ease state of the tissue and the experiments were con-
ducted 'blind'.
Antibodies
Anti-Oct-6 antibody 1 : rabbit polyclonal against the N-
terminal region of mouse Oct-6 protein (98% homology
in human), hereafter referred to as anti-Oct-6 (N). Anti-
body characterisation and specificity has been previously
described [4].
Anti-Oct-6 antibody 2 : rabbit polyclonal against full-
length Oct-6 purified from baculovirus infected Sf9 cells
hereafter referred to as Anti-Oct-6(FL). Antibody charac-
terisation and specificity has previously been described
[13].
Paraffin sections
Slides were dewaxed using xylene, rehydrated and endog-
enous peroxidase activity was blocked by washing in 0.3%
H2O2. Following PBS (phosphate buffered saline) washes,
slides were incubated in normal swine serum (1:10 in
Table 1: Summaries of demographic, clinical and histological information of schizophrenic, bipolar, major depression and control 
cases.
Demographics Group
Controls 
n = 15
Schizophrenic 
n = 15
Bipolar disorder 
n = 15
Major Depression 
n = 15
AGE (years, mean ± SD) 48.1 ± 10.7 44.5 ± 13.1 42.3 ± 11.7 46.5 ± 9.3
GENDER 9M, 6F 9M, 6F 9M, 6F 9M, 6F
POSTMORTEM INTERVAL (hours, mean ± SD) 23.7 ± 9.9 33.7 ± 14.6 32.5 ± 16.1 27.5 ± 10.7
CAUSE OF DEATH
CPD 13 7 11 8
Accident 2 0 0 2
Pneumonia 0 0 1 1
Suicide 0 7 1 1
O t h e r 0 123
pH (mean ± SD) 6.3 ± 0.2 6.2 ± 0.3 6.2 ± 0.2 6.1 ± 0.3
FIXATION (months, mean ± SD) 4.40 ± 3.9 11.20 ± 8.5 9.67 ± 3.6 8.33 ± 6.6
STORAGE OF FROZEN SECTIONS (days, mean ± S D) 621 ± 172.3 434 ± 290.0 338 ± 234.2 621 ± 233.1
BRAIN HEMISPHERE 7R:8L 6R:9L 8R:7L 6R:9L
DURATION OF ILLNESS (years, mean ± SD) 0 ± 0 21.3 ± 11.4 20.1 ± 9.7 12.7 ± 11.1
LIFETIME ANTIPSYCHOTICa DOSE (mg) (min-median-max) 0-0-0 0- 35 000- 200 000 0- 7 500- 60 000 0-0-0
a = lifetime quantity of fluphenazine or equivalent
CPD = cardiac pulmonary diseaseBMC Psychiatry 2005, 5:38 http://www.biomedcentral.com/1471-244X/5/38
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Oct-6 Immunorea ctivity in Paraffin-embedded Tissue from Control, Schizophrenic, Bipolar Disorder and Major Depression Figure 1
Oct-6 Immunoreactivity in Paraffin-embedded Tissue from Control, Schizophrenic, Bipolar Disorder and 
Major Depression. Oct-6 immunoreactivity was observed in hippocampal subfields CA4, CA3 and CA1 in controls (CON A 
– C), schizophrenics (SCH D – F), bipolar disorder (BP G – I) and major depression (MD J – L). Oct-6 immunoreactivity was 
observed in groups in a cytoplasmic/perinuclear fashion (arrowheads). Oct-6-positive cells had the morphological appearance 
of pyramidal neurons. Immunoreactivity is visible in the apical dendrites of some neurons (arrows in (H) and (K)) Scale bars = 
50 µmBMC Psychiatry 2005, 5:38 http://www.biomedcentral.com/1471-244X/5/38
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PBS; Dakocytomation) for 30 mins then incubated at 4°C
overnight in Anti-Oct-6(N) (1:500). Slides were then
incubated in anti-rabbit secondary (1:500 in PBS; Dakocy-
tomation) for 2 hours. Slides were washed then incubated
in ABComplex (Dakocytomation) for a further 2 hours in
the dark. Colour was developed using DAB (3, 3'-diami-
nobenzidine, Vector Laboratories). The reaction took 5–
10 minutes and was considered complete when a brown
colour was observed on the slides. When suitable colour
had developed, the DAB reaction was stopped by washing
slides in dH2O, slides were air dried and mounted using
Faramount aqueous mounting medium
(Dakocytomation).
Frozen sections
Slides were post fixed for 10 minutes in acetone (-20°C)
for 10 minutes, air dried and washed in PBS (4°C) for 5
minutes and 0.3% H2O2  for 10 minutes. Slides were
blocked for 30 minutes in a 1:10 (in PBS) solution of
Swine serum (Dakocytomation) and incubated overnight
at room temperature in anti-Oct-6(FL) (1:3000). Slides
were washed then incubated in anti- rabbit secondary
antibody (1:500, Dakocytomation) for 2 hours. Signal
amplification and visualization using ABC and DAB was
as described above.
In Situ Hybridization
In situ hybridization was conducted using a 1.6 kb DIG
labelled probe complementary to the 3' untranslated
region of the Oct-6 gene.
Forward primer:
GTGGTGGTGGTGGTGGTGTGTGACGGG
Reverse primer:
ACAGCCCTGGGGTACATGTTTATGTGAGTAATAAAAT
Amplicon: 1646 bp
Slides were placed in 4% fomaldehyde at room tempera-
ture for 10 mins then washed in DEPC-PBS then in 0.1 M
triethanolamine, pH 8.0/acetic anhydride, 400: 1 (vol:
vol), on a stir plate for 10 min. Slides were then incubated
in pre-hybridization solution (50% formamide, 5 × SSC,
5 × Denharts, 250 µg/ml bakers yeast RNA and 500 µg/ml
Herring sperm DNA) for 2–4 hrs at room temperature in
a humidified chamber. Slides were incubated in hybridi-
zation solution (pre-hybridization solution with probe
added at a typical concentration of 1:500), covered with a
coverslip and incubated at 60°C for approximately 18
hours. Sense-strand probes were used as specificity con-
trols for hybridization and revealed no binding.
Coverslips were removed by washing in 5 × SSC at 65°C,
then the slides were washed in 2 × SSC at 65°C for 30
mins, 0.2 × SSC at 65°C for 30 mins, then in Buffer 1 (0.1
M Tris pH7.5, 0.15 M NaCl) for 5 mins then incubated in
block (10% heat inactivated sheep serum in Buffer 1) at
room temperature for 1 hour then finally incubated in
alkaline phosphatase-conjugated sheep anti-DIG anti-
body (Roche) at room temperature for 4 hours. Following
washed in Buffer 1 and Buffer 3 (0.1 M Tris pH9.5, 0.1 M
Oct-6 Immunoreactivity in the Cerebral Cortex Figure 2
Oct-6 Immunoreactivity in the Cerebral Cortex. Oct-6 immunoreactivity in the cerebral cortex of a schizophrenic 
patient. Staining was observed in a layer-specific pattern restricted to layers II/III and V (B) seen at higher magnification in (A) & 
(C). Oct-6-positive cells had the morphological characteristics of pyramidal neurones. In general, POU3F1 immunoreactivity 
was dispersed throughout the cell (asterisks in A), though some did have the cytoplasmic/perinuclear localization noted in the 
hippocampus (arrowheads in A). Immunoreactivity was also observed in the apical dendrites (arrows). Cells in layer V (C) 
appeared considerably smaller than those in layer II/III (A). A similar cortical expression was observed in all groups. Scale bars: 
(B) = 200 µm (A & C) = 50 µmBMC Psychiatry 2005, 5:38 http://www.biomedcentral.com/1471-244X/5/38
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Oct-6 Immunoreactivity in Fresh-frozen Tissue from Control, Schizophrenic, Bipolar Disorder and Major Depression Figure 3
Oct-6 Immunoreactivity in Fresh-frozen Tissue from Control, Schizophrenic, Bipolar Disorder and Major 
Depression. Oct-6 immunoreactivity was observed in all groups (CON A – C and CON (2) D- F), schizophrenics (SCH G – 
I), bipolar disorder (BP J – L) and major depression (MD M – O) and did not differ between groups or in comparison to con-
trols. Oct-6-positive cells had the morphological appearance of pyramidal neurons. In the CA4 and CA3 regions immunoreac-
tivity generally took on a nuclear localization (arrowheads) thought in some cases a more dispersed pattern of expression was 
noted (asterisks). Oct-6 immunoreactivity was also noted the apical dendrites of some cells (arrows). Though staining was 
robust throughout, it appeared stronger in the CA1 region (C, F, I, L & O), in all cases Oct-6 immunoreactivity in the CA1 was 
nuclear. Scale bars = 50 µmBMC Psychiatry 2005, 5:38 http://www.biomedcentral.com/1471-244X/5/38
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NaCl, 50 mM MgCl2, 2 mM levamisole), hybridization
was visualized by enzyme catalysed colour reaction using
nitro blue tetrazolium salt (NBT) and 5-bromo-4-chloro-
3-indolyl phosphate (BCIP) (Roche). Reaction was
stopped in PBS and then water, slides were air-dried and
mounted using Faramount aqueous mounting medium
(Dakocytomation).
Image analysis
All sections were analysed with a Nikon light microscope
(Eclipse 600) with Lucia 4.0 image analysis software.
Results
OCT-6 immunoreactivity in paraffin sections
We attempted to detect OCT-6 immunoreactivity in hip-
pocampus and cortex in post-mortem human brains. We
performed immunohistochemistry on a series of 22 paraf-
fin sections from the hippocampal formation taken from
a total of 20 brains from all four groups under study
(schizophrenia (n= 9), major depression (n = 3), bipolar
disorder (n = 3), and control (n = 5)), using the antibody
(Anti-Oct-6 (N)) and staining procedure as in the previ-
ous study [6]. In each case, we found OCT-6 expression in
all fields (CA4, CA3 and CA1) of the hippocampal forma-
Oct-6 mRNA expression in Control, Schizophrenic, Bipolar Disorder and Major Depression Patients Figure 4
Oct-6 mRNA expression in Control, Schizophrenic, Bipolar Disorder and Major Depression Patients. Oct-6 
mRNA expression (arrowheads) was observed in hippocampal fields CA4 (A, E, H & K), CA3 (B, F, I & L) and CA1 (C, G, J and 
M) in all groups including controls (controls = CON, schizophrenics = SCH bipolar disorder = BP and major depression = 
MD). No qualitative differences were noted in hybridization signal between different regions or groups. Oct-6 mRNA was 
observed in a layer-specific pattern in the cortical layers II/III and V (D). Scale bars: (D) = 500 µm, all others = 50 µmBMC Psychiatry 2005, 5:38 http://www.biomedcentral.com/1471-244X/5/38
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tion (Figure 1). OCT-6 immunoreactivity was restricted to
large cells with the morphology of pyramidal neurons and
appeared to be localised to the perinuclear region of the
cytoplasm. There was no distinguishable difference in
intensity of staining between different hippocampal
fields.
Immunoreactivity was also noted in the cerebral cortex
where it assumed a layer-specific pattern, appearing
restricted to pyramidal neurons of layers II/III and V (Fig-
ure 2). Cells in layer II/III were more intensely stained
than those in layer V. OCT-6 expression in all cortical neu-
rons generally appeared to be dispersed throughout the
cell, although a few neurons in layer II/III were noted to
have the cytoplasmic/perinuclear localization seen in hip-
pocampal cells (Figure 2A (arrowhead)). This laminar dis-
tribution in the neocortex is consistent with the pattern
described in adult rodents [3].
Thus, in contrast to the previous study [6], we observed
OCT-6 immunoreactivity in hippocampal field CA1 and
were unable to detect any difference in OCT-6 expression
between control and schizophrenic specimens, as all the
control specimens we examined (n = 5) displayed Oct-6
immunoreactivity.
OCT-6 immunoreactivity in frozen sections
The immunoreactivity in the paraffin sections was pre-
dominantly cytoplasmic. Though this has been reported
in earlier studies [6, 14], it is nonetheless noteworthy
since Oct-6 being a transcription factor would be expected
to be nuclear. It was deemed possible that the fixation
may be affecting antibody penetration. In order to inves-
tigate this further, immunohistochemistry was conducted
on fresh frozen sections. We were unable to observe any
immunoreactivity in unfixed specimens using the anti-
Oct-6 (N) antibody. We were, however, able to observe
robust, reproducible staining using the anti-Oct-6(FL)
antibody. Oct-6 immunoreactivity was observed in a sub-
set of cells in hippocampal fields CA4, CA3, CA1 in all
groups (Figure 4). As with the paraffin sections, staining
appeared restricted to pyramidal neurons. Not all speci-
mens had Oct-6 immunoreactive cells, but in each group
the majority of specimens were positive (6 of 7 control
specimens, 8 of 8 schizophrenic specimens, 6 of 7 bipolar
specimens and 7 of 8 major depression specimens). There
was no significant difference in the proportion of positive
specimens between groups.
In all positive cases staining was evident throughout the
hippocampal formation from CA4 to CA1, but different
fields showed different degrees of immunoreactivity with
the most intense staining generally appearing in CA1.
Differences in staining localization between the different
hippocampal fields were apparent. In some specimens,
Oct-6 immunoreactivity in CA4 and CA3 was present
throughout the neuron cell body (Figure 3A (asterisks),
whilst in others it was predominantly nuclear (Figure 3D,
E, J and 3K (arrows). Immunoreactivity was also noted in
the apical dendrites of some cells (Figure 3B (arrow-
heads). In all cases the intense staining seen in the CA1
region was predominantly nuclear (Figure 3C, F, I, L and
3O). These differences in localization did not appear to be
particularly associated with any of the four groups under
study.
In situ hybridization (ISH)
In order to determine areas of Oct-6 gene expression, ISH
was performed using a probe complementary to the
3'UTR of the Oct-6  gene.  Oct-6  mRNA expression was
observed in the cortex and all hippocampal fields in spec-
imens from all four groups (Figure 4). As with
immunoreactivity, the majority of specimens in each
group were positive (9 of 14 control specimens, 9 of 15
schizophrenic specimens, 9 of 14 bipolar specimens and
9 of 14 major depression specimens). Thus, the propor-
tion of positive specimens was almost identical in each
group.
Although levels of immunoreactivity varied between hip-
pocampal fields, the ISH signal appeared to be at similar
levels throughout, being equally intense in the CA4 as the
CA1 cells. There were some positive cells in cortical
regions, but intensity here was much reduced. In the cor-
tex the expression of Oct-6 mRNA was confined to layers
II/III and V, similar to the Oct-6 immunoreactivity
described above.
Statistical analysis of confounding variables
Kruskal-Wallis non-parametric tests revealed significant
differences between groups with regards to the length of
time tissue had spent either in formalin or in frozen stor-
age (df = 3 p = 0.017 and df = 3, p = 0.005 respectively) in
each case the control samples had spent shorter amounts
of time in each.
Discussion
In this study, we sought to reproduce the previously
reported finding that OCT-6 was expressed by pyramidal
neurons in the hippocampus of schizophrenic brains, but
not in controls [6]. We attempted to extend this finding to
include bipolar disorder and major depression. Using
immunoreactivity and ISH we observed Oct-6 expression
in all three disease states, but unlike the previous study we
also observed expression in the control group. So while
we can confirm that Oct-6 is indeed expressed by pyrami-
dal neurons in the schizophrenic brain (and in bipolarBMC Psychiatry 2005, 5:38 http://www.biomedcentral.com/1471-244X/5/38
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disorder and major depression), there is no observable
difference from controls.
Each of the three approaches use in this study gave subtly
different results in terms of the localisation of expression
and the proportions of specimens that express Oct-6.
These differences most likely reflect differences in the
techniques themselves, such as fixation. Note also that the
paraffin and frozen sections were from different sides of
the brain randomly chosen to limit laterality.
Nonetheless, no differences between the disease groups
and controls emerge with any technique.
The paraffin immunohistochemistry indicated that Oct-6
was expressed in all specimens, regardless of group. The
fresh frozen immunohistochemistry and ISH gave posi-
tive results in approximately 90% of cases. Therefore,
either there are a small number of Oct-6 negative brains,
or the fresh frozen sections gave occasional false nega-
tives. A second difference that emerges is that while ISH
detected a signal of similar intensity in all hippocampal
fields, the immunohistochemistry appeared to give a
stronger signal in CA1, though clear staining was observed
in all hippocampal fields. It is possible that this difference
in expression could be due OCT-6 stability or transla-
tional efficiency in the CA1. This is currently under inves-
tigation and we have observed evidence of translational
control of Oct-6  in studies in vitro (unpublished
observations).
The final difference to emerge from our studies was the
difference in localisation of immunoreactivity between
paraffin and frozen sections. In paraffin sections, the
immunoreactivity was exclusively cytoplasmic, whilst in
frozen sections it was predominantly nuclear. The cyto-
plasmic expression was somewhat unexpected for a tran-
scription factor, but not unprecedented. Some
transcription factors are regulated by sequestration in the
cytoplasm, NFêB for example [15], and a cytoplasmic
localisation for Oct-6  has previously been reported in
Schwann cells. It was also possible; however, that the
absence of nuclear staining was an artefact of fixation, and
the fact that we observe nuclear staining in the fresh fro-
zen sections supported this notion.
It is important to note that, despite the fact that no defi-
nite statements regarding the cellular localization of Oct-
6 immunoreactivity can be made, Oct-6 immunoreactiv-
ity was observed in similar regions all groups including
controls, regardless of the fixation method used. The
expression of Oct-6 mRNA coincided with protein expres-
sion and again was observed in all groups including con-
trols. Taken as a whole, the data from this study strongly
argue against Oct-6 being a marker of schizophrenia or
any other psychiatric condition.
Our overall observations are consistent with Oct-6 expres-
sion seen in the rodent [3,4], with the one difference that
in the adult rodent Oct-6 expression becomes restricted to
the CA1 field of the hippocampus and layer V of the cere-
bral cortex with age, whereas we see expression in all fields
of the human hippocampal formation. It is possible that
the restriction may have yet to occur in the brains we
investigated, but in rodents the adult pattern is observed
by postnatal day 30 [3] while our specimens had an aver-
age age of 45, so this explanation is unlikely.
It is unclear why we have been unable to reproduce the
earlier result. The few negative specimens seen with fresh
frozen sections suggest that Oct-6-ve specimens may occur
and thus it is conceivable that all the controls in the pre-
vious study were genuinely Oct-6-ve. Unfortunately, we do
not have access to these earlier specimens in order to ver-
ify this point. Another possibility is that the specimens
used by Ilia et al (2002) [6] were different in terms of
some other significant uncontrolled variable. We have
compared the two groups of specimens and have been
unable to identify such a variable. A comparison of the
ages of control specimens, for example, indicated no dif-
ference between the two (df = 23, p= 0.0913).
Conclusion
The expression of Oct-6, both mRNA and protein, in the
majority of samples including controls would seem to
suggest that the expression we observe is a reflection of
normal Oct-6 expression in the adult. We conclude there-
fore that Oct-6, rather than being a specific biological
marker of schizophrenia, or any other psychotic state, is
likely to be normally expressed in the adult brain.
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